The New Eppendorf Tubes® 5.0 mL with Screw Cap
2016 AACC Annual Meeting Press ProgramThe introduction of this new screw cap container represents the latest significant innovation within the Eppendorf Tubes® 5.0 mL system.
The introduction of this new screw cap container represents the latest significant innovation within the Eppendorf Tubes® 5.0 mL system.
Eppendorf’s new refrigerated Centrifuge 5920 R combines extraordinary high capacity with enhanced temperature management in a very compact and ergonomic product design.
Festo features at AACC 2016, July 31- Aug. 4 in Philadelphia, the company’s automation solutions for clinical diagnostic equipment. Festo automation lowers manufacturer engineering costs and boosts diagnostic speed and overall performance. (Festo AACC Booth #3939)
Medical Electronic Systems (www.mes-global.com) is a Los Angeles based technology company specializing in rapid, automated semen analysis for the human and the veterinary markets. The MES line of CE and FDA cleared Sperm Quality Analyzers, complementary testing kits and disposable testing supplies are sold through an extensive network of international distributors. MES is ISO certified as a medical manufacturer and has wholly owned distribution offices in America, Europe, China and Israel.
The Clinical Laboratory Automation Module (CLAM-2000) is a fully integrated sample pretreatment module for LC-MS. The system automatically performs all of the processes necessary for analyzing blood and other biological samples, from scanning in information from the blood collection tubes to sample pretreatment and LCMS analysis.
Advanced Instruments, Inc., a leader in laboratory instrumentation, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its GloCyte Automated Cell Counter System and GloCyte Low and High Level Controls.
AACC released a position statement today on the need to improve pediatric reference intervals, which play a crucial role in ensuring that children receive accurate medical diagnoses and effective treatment. The statement calls on Congress to mandate and fund a national repository of specimens from healthy children, which the clinical laboratory community needs to develop precise reference intervals.
On June 17, the Centers for Medicare and Medicaid Services (CMS) released the final rule implementing the clinical laboratory provisions of the Protecting Access to Medicare Act (PAMA) of 2014, which will make the most significant changes to medical test reimbursement that clinical laboratories have seen in three decades. AACC applauds CMS for delaying full enactment of these reforms until 2018, a delay AACC had encouraged to give labs time to prepare for the new payment system and ensure that patient access to critical tests is not hindered.
AACC is pleased to announce that Theranos founder and CEO Elizabeth Holmes will give a plenary presentation at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia. For the first time, Holmes will present data at a scientific conference that describes Theranos’ technologies, including small sample volume testing and finger-stick collection.
Today, AACC, the March of Dimes, and 66 other major healthcare organizations called for Congress to provide immediate emergency funding to prepare for potential Zika outbreaks in the U.S. by strengthening laboratory testing and rapid response capabilities for the virus. The organizations assert that this is a crucial step toward protecting pregnant women and infants from this devastating infection.
In response to calls for the Food and Drug Administration (FDA) to regulate laboratory-developed tests, AACC released a position statement today strongly recommending that the Clinical Laboratory Improvement Amendments (CLIA) remain the primary mechanism for overseeing these tests. CLIA has a proven track record of ensuring that labs provide accurate test results that enable patients to receive the care they need, and its regulations can be modified easily to enhance oversight of laboratory-developed tests without endangering patient access to this indispensable service.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2016 AACC and National Academy of Clinical Biochemistry (NACB) Awards. Through this annual awards program, AACC and its academy, NACB, recognize individuals worldwide for exceptional research and service in the field of laboratory medicine, and aim to raise awareness that laboratory testing is essential to high quality patient care.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Robert Christenson, PhD, DABCC, FACB, will assume the position of editor-in-chief for AACC’s new journal, The Journal of Applied Laboratory Medicine: An AACC Publication, effective January 24.
Advances in a powerful lab technology known as mass spectrometry are beginning to revolutionize all areas of medical testing. The Mass Spectrometry issue of Clinical Chemistry, the journal of AACC, showcases the breadth of this technology’s impact on patient care—from making it easier to determine whether diabetes patients are at risk for life-threatening cardiovascular events, to reducing the amount of surgical procedures cancer patients must undergo.
Medical testing has been undergoing a quiet but extensive metamorphosis as labs adopt the versatile technology mass spectrometry, which enables more precise diagnosis. A special issue of Clinical Chemistry, the journal of AACC, titled “Clinical Mass Spectrometry: Achieving Prominence in Laboratory Medicine,” showcases the recent medical advances that this technology has made possible, from the development of new screening methods for designer drugs to a surgical knife that detects cancerous tissue.
The Mass Spectrometry issue of Clinical Chemistry, the journal of AACC, features pioneering research that could enable screening for two synthetic cannabinoids that are on the rise. This study could also help to reduce the popularity of designer drugs overall by making it easier to develop tests for the myriad of new, dangerous substances that emerge every year.
For the first time, researchers have developed tests that could improve the diagnosis of two rare childhood diseases known as congenital disorders of glycosylation (CDGs) and metachromatic leukodystrophy, and that could even lead to new treatments for CDGs. The findings were published in the Mass Spectrometry issue of Clinical Chemistry, the journal of AACC.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Bradley Pine has been named vice president of education and meetings, effective today.
Today, AACC sent a letter to the House Energy & Commerce leadership in response to draft legislation proposing additional federal oversight of laboratory developed tests. In its statement, AACC recommended modifying the current regulatory structure for these tests instead of introducing costly, burdensome regulation that could hinder patient care.
AACC is pleased to announce that Stephen Poston has assumed the newly-created position of chief information officer (CIO) for the association, effective today. Prior to joining AACC, Poston served as director of information technology and office services at the Endocrine Society, an organization representing more than 18,000 scientists and clinicians. At the Endocrine Society, Poston directed multiple high-impact IT projects including a major undertaking to enhance the value of membership by replacing the Society’s association management system software.
AACC is pleased to announce that Michael J. Bennett, PhD, has been elected to serve on the AACC Board as president-elect beginning in January 2016, followed by successive terms as the association’s 68th president in 2017 and past president in 2018. The AACC membership also elected a new treasurer and two new members of the association’s Board of Directors who will take office at the start of 2016.
Join the American Association for Clinical Chemistry (AACC) and leading experts in laboratory medicine and diagnostic testing for a discussion of how laboratory medicine is driving the future of personalized medicine and the policies to support these new technologies.
Today, the National Academy of Medicine (formerly the Institute of Medicine) released a comprehensive report on patient harm caused by diagnostic error that outlines the scope of this serious issue as well as potential solutions. AACC strongly supports the report’s findings that cohesive communication between all members of the healthcare team could help reduce these errors—a goal to which AACC and its members, laboratory medicine professionals, have long been committed.
AACC welcomed thousands of medical professionals and healthcare leaders to the 2015 AACC Annual Meeting & Clinical Lab Expo in Atlanta from July 26–30. The meeting showcased revolutionary advancements in clinical testing technology and research that improves the ability of healthcare providers to diagnose patients quickly and accurately and make sure patients get effective medical treatment.
Clinical laboratory tests play a crucial role in making sure patients get appropriate care, yet many small labs and clinics in low resource settings cannot afford the instruments needed to provide these tests. Research on a novel fingerprick test that can perform all common clinical diagnostics could help to expand access to basic medical testing in the developing world, and will be featured at the 2015 AACC Annual Meeting & Clinical Lab Expo.
At the 2015 AACC Annual Meeting & Clinical Lab Expo, researchers will present findings that a first-of-its-kind smartphone test for chlamydia can detect the disease with high accuracy, which could reduce the prevalence of this sexually transmitted disease (STD) by making chlamydia screening easier and cheaper.
Ortho-Clinical Diagnostics, Inc. (OCD) today announced the presentation of data for five assays under development. The assays address a range of important tests for clinical labs including HIV, acute kidney injury and cardiac troponin I. The scientific posters will be delivered during the 2015 American Association for Clinical Chemistry Annual Meeting to be held July 26 - 30 in Atlanta, Georgia.
Hair samples can be used to measure the effects of asthma on the cortisol levels of women during pregnancy, according to research presented today at the 2015 AACC Annual Meeting & Clinical Lab Expo in Atlanta. This research also shows that levels of cortisol, a stress-related hormone, tend to be lower among pregnant women with asthma than among pregnant women without the chronic, inflammatory lung disease.
Researchers have successfully tested two new potential methods for diagnosing and monitoring diabetes in its standard and gestational forms. These findings, presented today at the 2015 AACC Annual Meeting & Clinical Lab Expo in Atlanta, may lead to easier, timelier, and more affordable ways of identifying and treating this chronic disease.
AACC is pleased to announce the recipients of the AACC 2015 Corporate Supporter Awards. Each year, AACC recognizes the companies and organizations that generously support the association through sponsorships, advertising, and exhibiting. These significant contributions make it possible for AACC to improve patient care by fostering research, innovation, and professional excellence in the field of laboratory medicine.
Research presented at the 2015 AACC Annual Meeting & Clinical Lab Expo will expand on the studies that led to a fingerprick Ebola test becoming the first and only rapid diagnostic for this disease to receive approval from the World Health Organization (WHO). This test could prove vital to breaking Ebola’s grip on West Africa by identifying suspected Ebola cases within minutes, and enabling healthcare workers to isolate and treat these patients much faster than is currently possible.
The Lee Company’s new Hard Seat VHS Micro-Dispense Valve features the speed and reliability of Lee’s traditional VHS valves, but the traditional elastomeric seal has been replaced with a precision zirconia ball and seat. The result is a valve offering precise, repeatable, non-contact dispensing in the nanoliter to microliter range which is well suited for DMSO and other fluids that typically react with elastomeric seals.
The High Density Interface (HDI) solenoid valve just got better by offering more flow capacity without sacrificing size and weight. Imagine the features of a large valve coupled with the superior performance of a miniature valve in one compact design
The Lee Company's new atomizing nozzles, available in both airless and air assisted styles, generate a 50° hollow cone spray pattern and offer precise, controlled atomization in a compact package.
Glycated Serum Protein bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured
The Double Ended Piston Pumps of Diener Precision Pumps allow up to two different liquids and two different flow or stroke volume displacement rates in one application. The pumps have a space and economical saving design. Diener Precision Pumps is the Swiss Quality pump and valve manufacturer specialized in customer tailored solutions.
The quality manufacturer of piston pumps and gear pumps Diener Precision Pumps, founded in 1994, was recertified according to the medical standards ISO 9001/ ISO 13485. On the company website, users are newly provided with a chart helping application engineers to evaluate the compatibility of different chemical substances.
UTAK Laboratories announces the release of their SMx™ (Specialty Matrix) Product Line. UTAK’s SMx™ Matrices replicate some of the most challenging Laboratory Testing Methodologies and have performed in real-life Laboratory conditions to a standard that is uniquely reserved for UTAK products.
Noting a paradigm shift among consumers who are seeking greater control over their own healthcare, AACC issued a position statement today on direct-to-consumer laboratory testing, which allows people to order medical tests directly from a lab without having to work with their healthcare provider. The statement emphasizes direct-to-consumer test results must be accurate and easily understood—an area where laboratory medicine professionals play a vital role.
The 2015 AACC Annual Meeting & Clinical Lab Expo, the leading annual event for laboratory medicine, will open on Sunday, July 26, in Atlanta, Georgia. This year’s meeting will host more than 400 educational sessions on topics ranging from personalized medicine and infectious diseases to point-of-care and laboratory-developed tests, and will feature more than 200 new cutting edge diagnostic products.
Streck will be a sponsor and exhibitor at the AACC Annual Meeting & Clinical Lab Expo. Streck has a number of new products this year; find us at booth #2552 to learn more
Visiun, Inc., the leader in performance analytics for the laboratory, is celebrating 5 years of proudly supporting the laboratory community and will be showcasing their feature-rich Performance Insight™ at the AACC Clinical Lab Expo, taking place July 28-30, at the Georgia World Congress Center in Atlanta, Georgia
— Visiun, Inc., the leader in performance analytics for the laboratory, announced today that the Compass Group has awarded them a sole source agreement for business intelligence software for their 26 health systems, encompassing over 380 hospitals nationwide. Following a vendor evaluation process, the Compass Group selected Visiun’s feature-rich Performance Insight™.
Parker Hannifin Corporation announces the release of the R9 Diaphragm Rocker Isolation Liquid Valve, a family of 9 mm valves that improves performance of Clinical Diagnostic, Analytical Chemistry and Agent Detection systems requiring precision fluid control
Enigma Diagnostics Ltd. (Enigma) and Beijing Leadman Biochemistry Co., Ltd. (Beijing Leadman) (SZSE:300289) signed a joint venture agreement with the principal goal of delivering the Enigma MiniLab molecular diagnostic Point-of-Care platform into the Chinese health care market to support its growing diagnostic needs.
The BBI Group (BBI) today announced it has developed in collaboration with the Defence Science and Technology Laboratory (Dstl) and licensed, through technology transfer company Ploughshare Innovations, a rapid test for Ebola. The assay, which is in the process of being verified to allow EUA submission, will be used to test patients suspected of Ebola infection to screen and potentially help with how they are subsequently managed. The test, utilising lateral flow technology, can provide a result in approximately 20 minutes.
As BBI Solutions (BBI) prepare for its 25th consecutive attendance at AACC, visitors to the BBI booth can expect to discover the increasing importance of high quality biological raw materials in driving assay performance and how BBI’s new, innovative products can help achieve this.
Today Siemens Healthcare Diagnostics reveals its latest in vitro diagnostic solu-tions—including the recently FDA-cleared ADVIA Centaur XPT Immunoassay Sys-tem1—at the 2015 AACC Annual Meeting and Clinical Lab Expo, Atlanta, July 26–30. In addition to featuring its portfolio of multidisciplinary solutions designed for use in hospital, reference, and physician office laboratories and near patients’ bedsides, the booth will highlight how Siemens’ customers around the world are achieving their clinical and workflow goals.
Over 70 world renowned experts in the field of antimicrobial resistance met in Annecy for the 5th edition of the World HAI/Resistance Forum, sponsored by bioMérieux, a world leader in the field of in vitro diagnostics and leader in microbiology. The Forum provided the opportunity to share their global experience and expertise in antimicrobial resistance in humans, animals, the environment and food. The discussions confirmed the need to create synergies between these different sectors. As resistance impacts both people and animals, coordinated action between human and veterinary medicine is essential to effectively combat this global public health threat. The experts also underlined the need for education of healthcare professionals as well as other user targets. They proposed a series of concrete, innovative educational actions, and selected as a priority the development of an international project, which bioMérieux committed to support.
bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the introduction of its new FDA-cleared tests to rapidly detect Lyme Disease in just 27 minutes.